{"log_id": 3805137502613828449, "direction": 0, "words_result_num": 78, "words_result": [{"probability": {"variance": 0.004706, "average": 0.963632, "min": 0.710261}, "location": {"width": 310, "top": 127, "height": 34, "left": 732}, "words": "注射用伏立康唑说明书第11页/共13"}, {"probability": {"variance": 0.008983, "average": 0.964728, "min": 0.52539}, "location": {"width": 842, "top": 148, "height": 46, "left": 207}, "words": "体外伏立康唑对曲檬菌属具有杀菌作用在一项开放、随机、多中心的研究中,比较了伏立康唑和两性霉素B在277例免疫功"}, {"probability": {"variance": 0.015331, "average": 0.957278, "min": 0.457383}, "location": {"width": 877, "top": 170, "height": 43, "left": 173}, "words": "能减退的急性侵袭性曲霉病患者中的疗效和生存受益,疗程为12周,治疗组和对照组的总有效率分别为53%和31%(基线时异常的"}, {"probability": {"variance": 0.004294, "average": 0.972995, "min": 0.593164}, "location": {"width": 872, "top": 190, "height": 44, "left": 174}, "words": "症状体征以及影像学皮气管镜检查完全或部分恢复正常),治疗组较对照组84日生存率显著为高。此外,伏立康唑在死亡时间和因"}, {"probability": {"variance": 0.007253, "average": 0.976769, "min": 0.496837}, "location": {"width": 536, "top": 222, "height": 33, "left": 174}, "words": "性停药的时间方面均有显著忧势,这种优势具有显著的临床意义和统计学意义"}, {"probability": {"variance": 0.01643, "average": 0.96002, "min": 0.415487}, "location": {"width": 494, "top": 253, "height": 33, "left": 208}, "words": "项研究证实了早些时候的一项前嗜性研究的结果,后者的研究对象为伴有"}, {"probability": {"variance": 0.002138, "average": 0.978639, "min": 0.797948}, "location": {"width": 311, "top": 241, "height": 32, "left": 737}, "words": "不良危险因素的患者,包括移植物抗宿主病,特"}, {"probability": {"variance": 0.001311, "average": 0.975298, "min": 0.860789}, "location": {"width": 192, "top": 286, "height": 19, "left": 174}, "words": "别是颅内感染(通常死亡率为"}, {"probability": {"variance": 5.8e-05, "average": 0.9964, "min": 0.974076}, "location": {"width": 249, "top": 275, "height": 28, "left": 426}, "words": "患者,经本品治疗后获得了良好效果"}, {"probability": {"variance": 0.009428, "average": 0.968416, "min": 0.517775}, "location": {"width": 850, "top": 293, "height": 45, "left": 203}, "words": "本项研究包括了伴有骨髓移植、实体器官移植、血液系统恶性肿瘤、癌症或者艾滋病等基础疾病患者的脑部、窦、肺部曲霉病和"}, {"probability": {"variance": 0.000123, "average": 0.992155, "min": 0.97}, "location": {"width": 88, "top": 338, "height": 21, "left": 174}, "words": "播散性曲病"}, {"probability": {"variance": 3.5e-05, "average": 0.995835, "min": 0.981899}, "location": {"width": 151, "top": 370, "height": 21, "left": 188}, "words": "重的难治性念珠菌感染"}, {"probability": {"variance": 0.010831, "average": 0.962147, "min": 0.473552}, "location": {"width": 849, "top": 379, "height": 48, "left": 201}, "words": "本项研究包括有55例严重的难治性念珠菌感染患者(包括念珠菌血症、播散性和其它侵袭性念珠菌病),这些患者以前已经过抗"}, {"probability": {"variance": 0.012648, "average": 0.947661, "min": 0.552816}, "location": {"width": 862, "top": 401, "height": 47, "left": 189}, "words": "菌治疗,特别是氟糜唑,但均无效。经伏立康唑治疗后有效者24例(15例治愈,9例好转)对氟康唑耐药的非白念珠菌菌株感染"}, {"probability": {"variance": 0.028079, "average": 0.911196, "min": 0.377386}, "location": {"width": 310, "top": 443, "height": 21, "left": 188}, "words": "中,33的克柔念珠菌(治愈)和6/8的光滑念"}, {"probability": {"variance": 0.011613, "average": 0.954842, "min": 0.63253}, "location": {"width": 151, "top": 436, "height": 20, "left": 498}, "words": "珠菌(5例治愈和1例"}, {"probability": {"variance": 0.004614, "average": 0.982883, "min": 0.67207}, "location": {"width": 334, "top": 422, "height": 32, "left": 694}, "words": "感染治疗有效。有限的药敏资料也支持了临床疗效"}, {"probability": {"variance": 0.006057, "average": 0.956169, "min": 0.699888}, "location": {"width": 195, "top": 475, "height": 22, "left": 174}, "words": "足放线病菌属和镰刀菌属感染"}, {"probability": {"variance": 0.000443, "average": 0.990478, "min": 0.913207}, "location": {"width": 245, "top": 504, "height": 23, "left": 202}, "words": "伏立康唑对以下罕见的真菌感染有效"}, {"probability": {"variance": 0.008051, "average": 0.969352, "min": 0.499144}, "location": {"width": 725, "top": 519, "height": 45, "left": 202}, "words": "足放线病南:伏立康唑治疗组中,28例尖端足分支霉菌感染者中治疗有效者16例(6例治愈,10例好转"}, {"probability": {"variance": 0.003522, "average": 0.969207, "min": 0.836751}, "location": {"width": 91, "top": 517, "height": 19, "left": 959}, "words": "例多育足分支"}, {"probability": {"variance": 0.012551, "average": 0.947132, "min": 0.583566}, "location": {"width": 474, "top": 549, "height": 33, "left": 173}, "words": "感染患者中2例治疗有效(均为好转)。此外,3例混合《1种以上病"}, {"probability": {"variance": 0.019928, "average": 0.951816, "min": 0.454793}, "location": {"width": 322, "top": 537, "height": 31, "left": 692}, "words": "其中包括足放线病菌属)感染者中1例治疗有效"}, {"probability": {"variance": 0.015746, "average": 0.939674, "min": 0.364899}, "location": {"width": 840, "top": 568, "height": 46, "left": 201}, "words": "镰刀断:伏立康唑治疗组17例患者,7例有效(3例治愈,4例好转)这7例患者中,3例为眼感染,1例为爽感染,3例"}, {"probability": {"variance": 0.004399, "average": 0.970518, "min": 0.683798}, "location": {"width": 553, "top": 598, "height": 37, "left": 173}, "words": "播散性感染,另有4例患者为包括珠镰菌属在内的混合感染,其中2例治疗有效"}, {"probability": {"variance": 0.004351, "average": 0.972262, "min": 0.734899}, "location": {"width": 482, "top": 631, "height": 34, "left": 216}, "words": "述罕见病原菌感染中,大多数患者对原有的抗真菌治疗无效成不能耐受"}, {"probability": {"variance": 0.000328, "average": 0.979444, "min": 0.961333}, "location": {"width": 31, "top": 678, "height": 18, "left": 174}, "words": "疗程"}, {"probability": {"variance": 0.001294, "average": 0.985318, "min": 0.815899}, "location": {"width": 482, "top": 693, "height": 38, "left": 201}, "words": "临床试验中,561例您者伏立康唑的疗程超过12周,136例超过6个月"}, {"probability": {"variance": 1.1e-05, "average": 0.99535, "min": 0.988502}, "location": {"width": 88, "top": 740, "height": 20, "left": 175}, "words": "儿科用药经验"}, {"probability": {"variance": 0.002162, "average": 0.982987, "min": 0.693474}, "location": {"width": 852, "top": 744, "height": 51, "left": 202}, "words": "用伏立康唑治疗61例确诊或高度怀疑为侵袭性真菌感染的儿科患者,年龄为9个月到15岁,其中212岁者34例,12-15岁"}, {"probability": {"variance": 8e-06, "average": 0.9956, "min": 0.992227}, "location": {"width": 44, "top": 792, "height": 17, "left": 182}, "words": "20例"}, {"probability": {"variance": 1e-06, "average": 0.998783, "min": 0.997316}, "location": {"width": 43, "top": 822, "height": 19, "left": 203}, "words": "大多数"}, {"probability": {"variance": 0.012922, "average": 0.957781, "min": 0.363023}, "location": {"width": 737, "top": 797, "height": 43, "left": 313}, "words": "想儿应用过其他抗真菌药物,但均失败在治疗性研究中包括了5例12-15岁的患儿,其余儿则在安慰性"}, {"probability": {"variance": 0.004344, "average": 0.981998, "min": 0.548821}, "location": {"width": 833, "top": 817, "height": 48, "left": 174}, "words": "用药中接受了伏立康唑治疗,这些想儿的基础疾病包括血液系统恶性肿瘤、再生障碍性贫血(27例)和慢性肉芽肿病(14例"}, {"probability": {"variance": 0.018742, "average": 0.934622, "min": 0.526295}, "location": {"width": 163, "top": 860, "height": 22, "left": 175}, "words": "感染中以曲霉病最为常见"}, {"probability": {"variance": 2e-06, "average": 0.997908, "min": 0.995654}, "location": {"width": 96, "top": 893, "height": 22, "left": 178}, "words": "【药代动力学】"}, {"probability": {"variance": 3.1e-05, "average": 0.997004, "min": 0.982376}, "location": {"width": 124, "top": 922, "height": 24, "left": 187}, "words": "般药代动力学特点"}, {"probability": {"variance": 0.009263, "average": 0.96416, "min": 0.587053}, "location": {"width": 852, "top": 929, "height": 49, "left": 202}, "words": "分别在健康受试者、特殊人群和患者中进行了伏立康唑的药代动力学研究。对伴有曲霉病危险因素(主要为淋巴系统或造血组织"}, {"probability": {"variance": 0.003397, "average": 0.974809, "min": 0.685817}, "location": {"width": 872, "top": 951, "height": 48, "left": 174}, "words": "的恶性肿瘤)的患者研究发现,每日2次口服伏立康唑,每次0.2g或0.3g,共14天,其药代动力学特点(包括吸收快,吸收稳定"}, {"probability": {"variance": 5.3e-05, "average": 0.994837, "min": 0.967799}, "location": {"width": 341, "top": 987, "height": 32, "left": 174}, "words": "体内积和非线性药代动力学)与健康受试者一致"}, {"probability": {"variance": 0.011138, "average": 0.956217, "min": 0.540077}, "location": {"width": 461, "top": 1013, "height": 35, "left": 207}, "words": "由于伏立康唑的代谢具有可饱和性,所以其药代动力学呈非线性,暴露"}, {"probability": {"variance": 0.029477, "average": 0.710507, "min": 0.46984}, "location": {"width": 73, "top": 995, "height": 37, "left": 743}, "words": "比例于"}, {"probability": {"variance": 0.02454, "average": 0.939255, "min": 0.524821}, "location": {"width": 123, "top": 1003, "height": 22, "left": 868}, "words": "加的比例。因此如"}, {"probability": {"variance": 0.018949, "average": 0.946672, "min": 0.474648}, "location": {"width": 232, "top": 1021, "height": 27, "left": 814}, "words": "倍当给予受试者推荐的负荷剂"}, {"probability": {"variance": 0.013615, "average": 0.947693, "min": 0.553414}, "location": {"width": 167, "top": 1044, "height": 24, "left": 179}, "words": "囊从每日2次,每次0.2g"}, {"probability": {"variance": 0.059789, "average": 0.844977, "min": 0.422087}, "location": {"width": 82, "top": 1041, "height": 23, "left": 382}, "words": "到每次"}, {"probability": {"variance": 0.026292, "average": 0.890979, "min": 0.577455}, "location": {"width": 75, "top": 1036, "height": 17, "left": 581}, "words": "估计泰露量"}, {"probability": {"variance": 0.023748, "average": 0.907964, "min": 0.410274}, "location": {"width": 293, "top": 1060, "height": 27, "left": 193}, "words": "净脉滴注或1服)后,24小时内其药浓度"}, {"probability": {"variance": 0.000197, "average": 0.990316, "min": 0.96244}, "location": {"width": 75, "top": 1049, "height": 24, "left": 609}, "words": "如不给予负"}, {"probability": {"variance": 1.7e-05, "average": 0.995784, "min": 0.987145}, "location": {"width": 137, "top": 1043, "height": 19, "left": 913}, "words": "药后大多数受试者的"}, {"probability": {"variance": 7.9e-05, "average": 0.991081, "min": 0.974713}, "location": {"width": 102, "top": 1087, "height": 19, "left": 178}, "words": "血药浓度约在第"}, {"probability": {"variance": 0, "average": 0.942973, "min": 0.942973}, "location": {"width": 39, "top": 1082, "height": 22, "left": 353}, "words": "态"}, {"probability": {"variance": 0, "average": 0.998966, "min": 0.998949}, "location": {"width": 31, "top": 1120, "height": 18, "left": 174}, "words": "吸收"}, {"probability": {"variance": 0.013894, "average": 0.948005, "min": 0.636956}, "location": {"width": 122, "top": 1145, "height": 23, "left": 217}, "words": "服本品吸收迅速而"}, {"probability": {"variance": 0.031476, "average": 0.898902, "min": 0.363949}, "location": {"width": 642, "top": 1114, "height": 56, "left": 418}, "words": "血药峰口服后绝对生物利用度约为96%当多剂量给药,且与高脂肪餐同时"}, {"probability": {"variance": 2.9e-05, "average": 0.992502, "min": 0.986327}, "location": {"width": 73, "top": 1153, "height": 17, "left": 743}, "words": "胃液pH值"}, {"probability": {"variance": 0.005402, "average": 0.950311, "min": 0.808797}, "location": {"width": 77, "top": 1147, "height": 18, "left": 862}, "words": "本品吸收无"}, {"probability": {"variance": 0.007318, "average": 0.952964, "min": 0.691993}, "location": {"width": 185, "top": 1165, "height": 26, "left": 174}, "words": "服用时,伏立康唑的血药峰"}, {"probability": {"variance": 1.9e-05, "average": 0.995985, "min": 0.988592}, "location": {"width": 61, "top": 1156, "height": 22, "left": 587}, "words": "分别减少"}, {"probability": {"variance": 0, "average": 0.99959, "min": 0.999189}, "location": {"width": 31, "top": 1204, "height": 18, "left": 174}, "words": "分布"}, {"probability": {"variance": 0.010134, "average": 0.945136, "min": 0.616112}, "location": {"width": 232, "top": 1226, "height": 28, "left": 203}, "words": "稳态浓度下伏立康唑的分布容积为"}, {"probability": {"variance": 0.0088, "average": 0.969741, "min": 0.620074}, "location": {"width": 222, "top": 1218, "height": 27, "left": 467}, "words": "kg,提示本是在组织中广泛分布"}, {"probability": {"variance": 0.00138, "average": 0.97008, "min": 0.897737}, "location": {"width": 72, "top": 1256, "height": 17, "left": 175}, "words": "的脑脊液进"}, {"probability": {"variance": 0.009034, "average": 0.960757, "min": 0.624322}, "location": {"width": 326, "top": 1241, "height": 31, "left": 280}, "words": "检测,所有患者的脑脊液中均可检测到伏立康唑"}, {"probability": {"variance": 0.057218, "average": 0.752404, "min": 0.403517}, "location": {"width": 142, "top": 1236, "height": 40, "left": 710}, "words": "受理号CB"}, {"probability": {"variance": 6e-06, "average": 0.997124, "min": 0.994634}, "location": {"width": 30, "top": 1289, "height": 17, "left": 175}, "words": "代谢"}, {"probability": {"variance": 0.01238, "average": 0.932722, "min": 0.505523}, "location": {"width": 414, "top": 1305, "height": 32, "left": 237}, "words": "试验表明伏立糜唑通过肝脏细胞色素P450同工酶;CYP2C19"}, {"probability": {"variance": 0.018232, "average": 0.886748, "min": 0.523484}, "location": {"width": 222, "top": 1294, "height": 33, "left": 717}, "words": "和CYP3A4代谢.200"}, {"probability": {"variance": 0.00087, "average": 0.986008, "min": 0.899991}, "location": {"width": 268, "top": 1341, "height": 33, "left": 202}, "words": "伏立康唑的药代动力学个体间差异很大"}, {"probability": {"variance": 0.003681, "average": 0.972926, "min": 0.705076}, "location": {"width": 469, "top": 1366, "height": 39, "left": 205}, "words": "体内研究表明CYP2C19在本品的代谢中有重要作用,这种酶具有基因"}, {"probability": {"variance": 0.059145, "average": 0.672537, "min": 0.416573}, "location": {"width": 143, "top": 1361, "height": 36, "left": 727}, "words": "种备"}, {"probability": {"variance": 0.017742, "average": 0.959686, "min": 0.354243}, "location": {"width": 517, "top": 1387, "height": 39, "left": 175}, "words": "和人中的弱代谢者仅占3-5%。在健康白人和健康日本人中的研究表明:弱"}, {"probability": {"variance": 0.012291, "average": 0.954042, "min": 0.45235}, "location": {"width": 496, "top": 1409, "height": 37, "left": 174}, "words": "的暴露量高4倍,杂合子强代谢者的药物暴露量比纯合子强代谢者高2倍"}, {"probability": {"variance": 0.000288, "average": 0.989766, "min": 0.93801}, "location": {"width": 364, "top": 1446, "height": 32, "left": 203}, "words": "伏立康唑的主要代谢产物为N氧化物,在血浆中约占"}, {"probability": {"variance": 0.001341, "average": 0.98694, "min": 0.818961}, "location": {"width": 371, "top": 1429, "height": 36, "left": 613}, "words": "该代谢产物抗活性微弱,对伏立康唑的药理作用无显"}, {"probability": {"variance": 0.000112, "average": 0.989294, "min": 0.978692}, "location": {"width": 32, "top": 1491, "height": 18, "left": 174}, "words": "排泄"}, {"probability": {"variance": 0.001283, "average": 0.990236, "min": 0.834281}, "location": {"width": 306, "top": 1507, "height": 31, "left": 343}, "words": "脏代谢,仅有少于2%的药物以原形经尿排出"}, {"probability": {"variance": 0.006246, "average": 0.962411, "min": 0.785796}, "location": {"width": 56, "top": 1590, "height": 22, "left": 506}, "words": "362-02"}], "language": 3}